Nilfisk Holding A/S
Notification of major shareholding
Notification of major shareholding
Company Announcement
April 10, 2025
Announcement No. 10/2025
Notification of major shareholding
With reference to Section 30 of the Danish Security Trading Act, Nilfisk Holding A/S has been informed by UBS Group AG that UBS Group AG as of April 3, 2025, has increased its total holding of shares and financial instruments representing shares or rights over shares in Nilfisk as follows:
Share capital and voting rights | Holding in Nilfisk Holding previously | Holding in Nilfisk Holding after April 3, 2025 |
Share capital and voting rights attached to shares in % | 0.06% | 0.01% |
Share capital and voting rights through financial instruments in % | 0.16% | 6.14% |
UBS Group AG total share capital in % | 0.22% | 6.15% |
As of April 3, 2025, UBS Group AG directly or indirectly controls 1,669,069 shares/voting rights and other financial instruments in Nilfisk Holding A/S, corresponding to 6.15% of the share capital and voting rights in Nilfisk Holding A/S.
For further information, please contact:
Investor Relations: Cameron Hayes +45 2271 6217
Communications & Media Relations: Nynne Jespersen Lee +45 4231 0007
Attachments
Documents
Subscribe to releases from Globenewswire
Subscribe to all the latest releases from Globenewswire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Globenewswire
Zealand Pharma12.5.2025 07:00:00 CEST | Press release
Zealand Pharma to participate in upcoming healthcare investor conferences in May and June 2025
Clariant International Ltd12.5.2025 07:00:00 CEST | Press release
Clariant rejects Dow Europe’s allegations against four companies related to the 2020 competition law infringement
Jeito Capital12.5.2025 07:00:00 CEST | Press release
Jeito Capital Strengthens Leadership for Next Chapter of Growth: Mehdi Ainouche Promoted to Partner, Julien Elric to Senior Principal
Tecan Group AG12.5.2025 06:30:00 CEST | Press release
Q1 2025 Qualitative Update: Tecan reports performance in line with expectations and confirms outlook for full year 2025
Akero Therapeutics Inc.10.5.2025 16:00:00 CEST | Press release
Akero Therapeutics and HistoIndex Present New Analyses of Phase 2b HARMONY Trial in Oral and Poster Presentations at the EASL Congress 2025
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom